Shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price objective of $6.50 for the company and are forecasting that the company will post ($0.20) EPS for the current quarter, according to Zacks. Zacks has also assigned RXi Pharmaceuticals Corp an industry rank of 162 out of 265 based on the ratings given to related companies.

RXi Pharmaceuticals Corp (NASDAQ:RXII) traded down 2.56% during midday trading on Wednesday, reaching $0.57. 341,516 shares of the company’s stock traded hands. RXi Pharmaceuticals Corp has a 52-week low of $0.51 and a 52-week high of $3.27. The stock’s market cap is $12.61 million. The company’s 50-day moving average price is $0.64 and its 200-day moving average price is $0.87.

RXi Pharmaceuticals Corp (NASDAQ:RXII) last posted its earnings results on Thursday, May 11th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.08. On average, equities analysts predict that RXi Pharmaceuticals Corp will post ($1.77) EPS for the current fiscal year.

An institutional investor recently bought a new position in RXi Pharmaceuticals Corp stock. Hudson Bay Capital Management LP bought a new stake in RXi Pharmaceuticals Corp (NASDAQ:RXII) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 214,406 shares of the biotechnology company’s stock, valued at approximately $153,000. Hudson Bay Capital Management LP owned 3.25% of RXi Pharmaceuticals Corp as of its most recent SEC filing. Institutional investors own 7.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “RXi Pharmaceuticals Corp (RXII) Receives Average Rating of “” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/05/24/rxi-pharmaceuticals-corp-rxii-receives-average-rating-of-from-brokerages.html.

RXi Pharmaceuticals Corp Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

12 Month Chart for NASDAQ:RXII

Get a free copy of the Zacks research report on RXi Pharmaceuticals Corp (RXII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RXi Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.